Table 2.
Efficacy results at Week 208 of telbivudine treatment in the per-protocol population of 502 patients without genotypic resistance after 2-years of telbivudine treatment in the feeder studies
| HBV DNA <300 copies/mL at Week 24 | ||||||
|---|---|---|---|---|---|---|
| All patients | HBV DNA <300 copies/mL at Week 24 | Baseline HBVDNA <9 log10 and ALT ≥2 × ULN | Baseline HBV DNA <7 log10 | |||
| Week 208 Results | HBeAg-positive N = 293 | HBeAg-negative N = 209 | HBeAg-positive N = 162 | HBeAg-negative N = 179 | HBeAg-positive N = 39 | HBeAg-negative N = 94 |
| HBV DNA level <300 copies/mL, n (%) | 163/214 (76.2) | 141/164 (86.0) | 109/124 (87.9) | 126/144 (87.5) | 28/30 (93.3) | 68/77 (88.3) |
| ALT normalization, n (%) | 178/206 (86.4) | 129/144 (89.6) | 107/120 (89.2) | 112/126 (88.9) | 27/30 (90.0) | 56/61 (91.8) |
ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus. The denominator for each parameter reflects the number of patients available for assessment.